Use of the drug Cocarnit in patients after endoprosthetics of the hip and knee joints

Authors: Korzh N.A., Filippenko V.A., Leontyeva F.S., Tulyakov V.A., Bondarenko S.Ye.

State Institution «Institute of Spine and Joint Pathology named after M.I. Sytenko of Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine


The paper deals with the results of clinical studies of Cocarnit effectiveness in patients after replacement of large joints.

It is shown that in patients receiving Cocarnit in the postoperative period, there was noted a decrease in complaints of patients on somatic condition.

Patients positively evaluated Cocarnit, significant adverse events that caused drug withdrawal were not detected.

At Cocarnit administration the most studied laboratory parameters (content of glucose, β-lipoproteins, total chondroitin sulfates, TBA-products (MDA), activity of aspartate aminotransferase, alkaline phosphatase and γ-glutamyltransferase), indices of clinical blood analysis and leukocyte indices in the observations hadn’t significant differences from those of the control group, which confirms the good tolerability of this drug.

Use of Cocarnit in treatment regimens for patients after replacement of large joints led to a decrease in content of cholesterol, glycoproteins, TBA-products (malondialdehyde), activity of alanine aminotransferase, indicating a normalizing effect of this drug on the major types of metabolism.

Key words: Cocarnit, biochemistry, clinical researches.

Download article in PDF (Ru)

Аренда яхты